Overview
- Species: Human
- Features: male, TARGATT
- Product Type: Exosomes
- Storage:-80°C freezer immediately upon receipt
hiEx™ Research iPSC Exosome Services
Cat.-Nr.: hiEX-custom
Description
Customize iPSC-derived exosomes for targeted insight and innovation
Through Applied StemCell’s hiEX™ Research iPSC Exosome platform, we provide tailored iPSC-derived Exosome Services to align design and formulation with your research goals.
Whether you require engineered exosomes for therapeutic payload delivery, enrichment with specific miRNAs or proteins, or lineage-specific differentiation prior to harvest, we can tailor your hiEX™ iPSC Exosomes to meet your project needs.
We also offer custom formulation options and the ability to scale into GMP manufacturing for clinical applications.
From basic research to early-stage discovery to preclinical development, custom hiEX™ iPSC Exosomes give you a flexible, future-ready solution for advancing your scientific programs.
Discover how our iPSC Exosome Services can advance your research with customized exosomes. Learn more below under the FAQ section.
SUPPLIER:
Applied StemCell
STATUS:
In Stock
hiEx™ Research iPSC Exosome Services
Related Files
References
- Wang AYL. Human Induced Pluripotent Stem Cell-Derived Exosomes as a New Therapeutic Strategy for Various Diseases. Int J Mol Sci. 2021;22(4):1769. doi:10.3390/ijms22041769
- Germena G, Hinkel R. iPSCs and Exosomes: Partners in Crime Fighting Cardiovascular Diseases. J Pers Med. 2021;11(6):529. doi:10.3390/jpm11060529
- Jeske R, Bejoy J, Marzano M, Li Y. Human Pluripotent Stem Cell-Derived Extracellular Vesicles: Characteristics and Applications. Tissue Eng Part B Rev. 2020;26(2):129-144. doi:10.1089/ten.teb.2019.0252
- Aldali F, Yang Y, Deng C, et al. Induced Pluripotent Stem Cell-Derived Exosomes Promote Peripheral Nerve Regeneration in a Rat Sciatic Nerve Crush Injury Model: A Safety and Efficacy Study. Cells. 2025;14(7):529. doi:10.3390/cells14070529
- Abbas A, Huang X, Ullah A, et al. Enhanced spinal cord repair using bioengineered induced pluripotent stem cell-derived exosomes loaded with miRNA. Mol Med. 2024;30(1):168. doi:10.1186/s10020-024-00940-6
- Oh M, Lee J, Kim YJ, Rhee WJ, Park JH. Exosomes Derived from Human Induced Pluripotent Stem Cells Ameliorate the Aging of Skin Fibroblasts. Int J Mol Sci. 2018;19(6):1715. doi:10.3390/ijms19061715
- Chi PL, Cheng CC, Wang MT, et al. Induced pluripotent stem cell–derived exosomes attenuate vascular remodelling in pulmonary arterial hypertension by targeting HIF-1α and Runx2. Cardiovasc Res. 2024;120(2):203-214. doi:10.1093/cvr/cvad185
- Lu M, Peng L, Ming X, et al. Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts. eBioMedicine. 2019;42:443-457. doi:10.1016/j.ebiom.2019.03.011
- Wang S, Hou Y, Li X, et al. Comparison of exosomes derived from induced pluripotent stem cells and mesenchymal stem cells as therapeutic nanoparticles for treatment of corneal epithelial defects. Aging. 2020;12(19):19546-19562. doi:10.18632/aging.103904
FAQs
Overexpress one or more genes in the parent iPSC line using powerful TARGATT™ large knock-in technology
Developed by the innovators at Applied StemCell, TARGATT™ large knock-in technology is used in many of our cell line engineering projects to overexpress one or more genes in mammalian cells.
With the ability to efficiently and site-specifically knock-in up to 20 kb of DNA in a single reaction—more in nested reactions—TARGATT™ technology is a highly effective way to engineer iPSCs so that your exosomes are enriched for a specific protein or miRNA.
Get a consistent source of human exosomes by differentiating the parent iPSCs before exosome isolation
The power of iPSCs lies in their ability to provide a consistent and scalable source of human cells that are morphologically and functionally similar to the equivalent primary cell.
Before isolating exosomes, we can differentiate the parent iPSC line into the cell type of your choice. The exosomes we isolate will have the batch-to-batch consistency you can’t get if you isolate exosomes from tissue originating from different donors.
Get exosomes from custom engineered cell-based models of disease
We routinely build cell-based models of disease by editing iPSCs and then differentiating into the desired cell type.
By combining our gene editing and iPSC expertise, we can efficiently create custom cell-based disease models and then isolate exosomes, to achieve your research goals.
Get exosomes from our hypoimmunogenic iPSC line
Explore the therapeutic and immunogenic potential of exosomes isolated from our knock-in ready hypoimmunogenic iPSC line, ActiCells™ RUO TARGATT™ Hypo hiPSCs.
We can isolate exosomes directly from this line or engineer the line to your specifications, including using our powerful TARGATT™ large knock-in technology for efficient site-specific integration and expression of your gene(s) of interest.
Manufacture hiEX™ Exosomes in a GMP-compliant environment
Our hiEX™ Research iPSC Exosomes are derived from ActiCells™ GMP TARGATT™ iPSCs, and GMP-compliant manufacturing can be considered on a case-by-case basis. Contact us to discuss your project needs.
Customize the formulation of your hiEX™ Exosome order
Off-the-shelf hiEX™ Research iPSC Exosomes come in vials of 10 × 10⁹ particles in 1 mL of PBS, but concentrations and formulations can be modified as needed, for example through lyophilization or the inclusion of specific ingredients such as hyaluronic acid
